entity

anti-amyloid antibodies

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about anti-amyloid antibodies: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

4Connections

0Hypotheses

4Analyses

4Outgoing

0Incoming

0Experiments

5Debates

No AI portrait yet

Outgoing (4)

Target	Relation	Type	Str
Alzheimer's_disease	associated_with	disease	0.90
ARIA risk	risk_factor_for	phenotype	0.70
CAA	targets	gene	0.70
AD	therapeutic_target_for	disease	0.70

Incoming (0)

Source	Relation	Type	Str
No incoming edges

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (4)

Scientific analyses that reference this entity

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.629

What molecular mechanisms explain how apoE promotes cerebral amyloid angiopathy

neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.766

Blood-brain barrier antibody transport mechanisms

neurodegeneration | 2026-04-02 | 8 hypotheses Top: 0.800

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (5)

Multi-agent debates referencing this entity

What mechanisms govern antibody transport across the blood-brain barrier and how

closed · Rounds: 4 · Score: 0.82 · 2026-04-22

What is the current clinical trial landscape for AD therapeutics, and which mech

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Is the amyloid concentration in AD clinical trials rational given lecanemab's ap

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

The study demonstrates that apoE is absolutely required for CAA development, as

closed · Rounds: 4 · Score: 0.71 · 2026-04-16

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06

Related Research

Hypotheses and analyses mentioning anti-amyloid antibodies in their description or question text

No additional research found